Chiral drugs are made up of molecules with the same chemical structure, but different three-dimensional arrangements. Modern manufacturing has enabled the development of products containing a single molecular arrangement. The development of these single enantiomers from chiral drugs is known as chiral switching. Enantiomers of the same drug can have different pharmacodynamic and pharmacokinetic properties. This may translate into potential health benefits, such as an improved safety margin, if one of the enantiomers has more favourable therapeutic and pharmacokinetic characteristics. However, some chiral switching has resulted in unpredicted toxicity and the withdrawal of the enantiomer from the market or a halt in its development. Drug companies are increasingly using chiral switching as a marketing strategy, but before prescribers switch to single enantiomer drugs they should look for evidence from well-conducted clinical trials that shows the chiral switch is cost-effective and improves the outcomes for patients rather than patents.
Introduction
Have you ever tried putting your left shoe on your right foot or your right glove on your left hand? Unless you intend to destroy the function of this apparel, you know you will not succeed.
Your left and right hands and feet are non-superimposable mirror images of one another. Chemicals including drugs can behave in a similar way. Many drugs consist of a mixture of left-and right-handed molecules (enantiomers), but there is an increasing trend for the pharmaceutical industry to develop and market products containing only the left-or right-handed molecule. 1 While many of these single enantiomer drugs (such
Definitions and chemistry
If a drug has a centre of asymmetry (usually a carbon atom with four different substituents), then it can exist as two non-superimposable left-handed and right-handed mirror images, also known as enantiomers. A racemate is a mixture of equal amounts of these two enantiomers. Many drugs are marketed as racemates. They are said to be chiral drugs (from the Greek word for hand, cheir).
There are different methods for naming enantiomers. The definitive way is to use the prefix (R)-(right hand) and (S)-(left hand). Other prefixes are (+) and (-) or D and L. An example is ibuprofen ( Fig. 1 ) which, as marketed in Australia, contains an equal amount of (R)-ibuprofen and (S)-ibuprofen.
Enantiomers have identical physical and chemical properties such as molecular weight, solubility and melting point. The only difference is their three-dimensional spatial configuration.
Enantiomer: one of a pair of stereoisomers that are non-superimposable mirror images of one another and therefore have a different 3-dimensional configuration
Isomers: compounds with the same molecular formula but with different 3-dimensional configuration
Racemate: a mixture of two enantiomers, usually in one-to-one ratio
Fig. 1
Ibuprofen is a racemic mixture of two non-superimposable mirror image enantiomers, (+)-(S)-ibuprofen and (-)-(R)-ibuprofen. The majority of the effects of racemic ibuprofen are elicited by (+)-(S)-ibuprofen. 
Pharmacodynamic differences between enantiomers
The interactions in the body between a drug and the proteins which elicit therapeutic or adverse effects and eliminate the drug require a specific three-dimensional configuration of drug and protein.
Since enantiomers have different three-dimensional configurations, the pharmacodynamics and pharmacokinetics of the two enantiomers which make up a racemic drug can be quite different. The differences often depend on whether the centre of asymmetry of the drug is in close proximity to the points of attachment to the protein. 
Pharmacokinetic differences between enantiomers
As the distribution and elimination of drugs from the body also involves their interaction with proteins, then the pharmacokinetics of enantiomers can also be different. For example:
n the bioavailability of (R)-verapamil is more than double that of (S)-verapamil due to reduced hepatic first-pass metabolism n the volume of distribution of (R)-methadone is double that of (S)-methadone due to lower plasma binding and increased tissue binding n the clearance of (R)-fluoxetine is about four times greater than (S)-fluoxetine due to a higher rate of enzyme metabolism n the renal clearance of (R)-pindolol is 25% less than (S)-pindolol due to reduced renal tubular secretion.
These differences in clearance and volume of distribution translate into differences in half-life. For example the half-life of (S)-fluoxetine is one quarter that of (R)-fluoxetine. In addition, these pharmacokinetic properties can be modified in a stereoselective manner by disease, genetics, ethnicity, age and other drugs. Finally, the enantiomers of some drugs such as warfarin can be metabolised by different enzymes.
Rationale for marketing chiral specific drugs
There are several possible health benefits to chiral switching. In some cases, chiral switching has been of no benefit.
For example, the clinical development of (R)-fluoxetine for depression (based on a more acceptable half-life and less propensity for significant drug-drug interactions) was stopped because of a small but statistically significant prolongation of the QT interval with high doses. Dilevalol was thought to have advantages over labetalol, but was removed from the Japanese market because of hepatotoxicity. 
Escitalopram
The selective serotonin reuptake inhibitor activity of citalopram and its active metabolites resides mainly in the (S)-enantiomer.
This enantiomer and its metabolites are eliminated slightly faster from the body than the (R)-enantiomer and its metabolites. In overdose, there is a concern about the potential for sudden 
